EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Physiology, pathology and therapeutic potential of microglial triggering receptor expressed on myeloid cells 2 signalling: A narrative update

Zhe Kong, Libin Shen, Daqing Ma, Jinchao Hou

Clinical and Translational Discovery · 2026-06 · 6 (3)

DOI: 10.1002/ctd2.70140 ↗

At a glance

Journal article in Clinical and Translational Discovery, published online on 2026-04-29. Written by Zhe Kong and 3 co-authors. Cited 1 times so far (Crossref); 139 references. The full text is freely available (open access, CC BY 4.0).

AbstractBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Triggering receptor expressed on myeloid cells 2 (TREM2) is a microglia‐enriched surface receptor that plays a central role in sensing lipid ligands and damage‐associated molecular patterns within the central nervous system. Growing evidence has expanded our understanding of TREM2 in both physiological homeostasis and a broad range of neurological disorders, and has further identified TREM2 as a promising therapeutic target.

Objective

This review aims to provide an updated overview of TREM2 signaling in microglial physiology and pathology, and to summarize the therapeutic potential of TREM2‐targeted interventions across neurological diseases.

Methods

A narrative synthesis of recent literature was performed to examine TREM2 signaling, its context‐dependent functions in both physiological and pathological states, and emerging advances in TREM2‐targeted therapeutic strategies for neurological disorders. Key Findings Under physiological conditions, TREM2 maintains microglial survival, homeostatic surveillance, and synaptic pruning. In pathological contexts, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, and glioblastoma, TREM2 signaling regulates microglial activation, promotes the clearance of pathological substrates, and shapes neuroinflammatory responses.

Conclusions

TREM2‐mediated microglial responses are highly context dependent and may exert distinct or even opposing functions across different disease types. A major challenge for future research is to tailor TREM2‐based interventions to the specific disease context, timing, and microenvironment in order to maximize their neuroprotective and immunomodulatory effects.

Cite

APA

Kong, Z., Shen, L., Ma, D., & Hou, J. (2026). Physiology, pathology and therapeutic potential of microglial triggering receptor expressed on myeloid cells 2 signalling: A narrative update. Clinical and Translational Discovery, 6(3). https://doi.org/10.1002/ctd2.70140

Vancouver

Kong Z, Shen L, Ma D, Hou J. Physiology, pathology and therapeutic potential of microglial triggering receptor expressed on myeloid cells 2 signalling: A narrative update. Clinical and Translational Discovery. 2026;6(3). doi:10.1002/ctd2.70140

BibTeX
@article{Kong2026,
  author = {Kong, Zhe and Shen, Libin and Ma, Daqing and Hou, Jinchao},
  title = {Physiology, pathology and therapeutic potential of microglial triggering receptor expressed on myeloid cells 2 signalling: A narrative update},
  journal = {Clinical and Translational Discovery},
  year = {2026},
  volume = {6},
  number = {3},
  doi = {10.1002/ctd2.70140}
}
Start for free →